Compare GSUN & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | LNAI |
|---|---|---|
| Founded | 1997 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 23.9M |
| IPO Year | 2022 | N/A |
| Metric | GSUN | LNAI |
|---|---|---|
| Price | $1.56 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 212.4K | ★ 3.1M |
| Earning Date | 02-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,314,724.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 526.22 | N/A |
| 52 Week Low | $1.25 | $0.81 |
| 52 Week High | $5.25 | $21.00 |
| Indicator | GSUN | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | N/A |
| Support Level | $1.29 | N/A |
| Resistance Level | $1.58 | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 72.09 | 0.00 |
Golden Sun Health Technology Group Ltd is a holding company. Along with its subsidiaries, it is engaged in the provision of education services and e-commerce business in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistics and consulting services. It has also established its wellness brands and an e-commerce platform to promote and sell wellness products. The company operates in the following segments; Education, which generates maximum revenue, and E-commerce.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.